Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$15.46 -0.1%	$15.55	$7.08 ▼ $17.49	$320.18M	0.84	93,165 shs	41,897 shs
CAPR Capricor Therapeutics	$6.27 +0.4%	$8.24	$3.98 ▼ $23.40	$286.74M	0.59	1.99 million shs	847,572 shs
CTMX CytomX Therapeutics	$2.06 -0.7%	$2.25	$0.40 ▼ $3.10	$338.90M	2.13	3.27 million shs	898,593 shs
EXOZ eXoZymes	$9.70 +4.2%	$9.90	$8.50 ▼ $23.99	$81.38M	N/A	1,237 shs	935 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.45%	-2.40%	+3.20%	+32.45%	+24.56%
CAPR Capricor Therapeutics	-3.40%	-12.83%	-7.95%	-38.06%	+30.62%
CTMX CytomX Therapeutics	+1.97%	+5.08%	-13.39%	-17.86%	+73.95%
EXOZ eXoZymes	+0.05%	-0.82%	-2.32%	-30.22%	+969,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.2644 of 5 stars	0.8	2.0	0.0	0.0	2.5	0.0	0.6
CAPR Capricor Therapeutics	3.0481 of 5 stars	4.6	2.0	0.0	0.0	2.3	0.8	0.6
CTMX CytomX Therapeutics	4.3621 of 5 stars	3.5	1.0	0.0	4.7	3.8	1.7	1.3
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.50	Reduce	$12.00	-22.38% Downside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	259.62% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	179.81% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EXOZ, AMRN, CAPR, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$77.00 ➝ $24.00
6/30/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$228.61M	1.40	N/A	N/A	$22.45 per share	0.69
CAPR Capricor Therapeutics	$13.39M	21.41	N/A	N/A	$2.30 per share	2.73
CTMX CytomX Therapeutics	$141.10M	2.40	$0.37 per share	5.61	$0.73 per share	2.82
EXOZ eXoZymes	$70K	1,162.61	N/A	N/A	$0.86 per share	11.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$82.18M	-$3.67	N/A	N/A	N/A	-47.22%	-21.18%	-15.00%	10/29/2025 (Estimated)
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-62.71%	-50.82%	11/12/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.56	3.67	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	-134.50%	-81.63%	N/A

Latest EXOZ, AMRN, CAPR, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
7/30/2025	Q2 2025	AMRN Amarin	-$0.66	-$0.03	+$0.63	-$0.03	$45.45 million	$72.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.26	2.34
CAPR Capricor Therapeutics	N/A	4.37	4.37
CTMX CytomX Therapeutics	N/A	4.20	4.20
EXOZ eXoZymes	0.01	6.19	6.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
CAPR Capricor Therapeutics	21.68%
CTMX CytomX Therapeutics	67.77%
EXOZ eXoZymes	N/A

Insider Ownership

Company	Insider Ownership
AMRN Amarin	3.30%
CAPR Capricor Therapeutics	10.50%
CTMX CytomX Therapeutics	6.60%
EXOZ eXoZymes	72.41%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	20.71 million	20.02 million	Optionable
CAPR Capricor Therapeutics	101	45.72 million	40.92 million	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A

EXOZ, AMRN, CAPR, and CTMX Headlines

Recent News About These Companies

eXoZymes (NASDAQ:EXOZ) Shares Down 4.8% - Here's Why

August 24, 2025 | marketbeat.com

eXoZymes (NASDAQ:EXOZ) Posts Quarterly Earnings Results

August 14, 2025 | marketbeat.com

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

August 12, 2025 | accessnewswire.comA

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

August 7, 2025 | accessnewswire.comA

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

July 29, 2025 | accessnewswire.comA

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

July 22, 2025 | accessnewswire.comA

Insider Buying: eXoZymes Inc. (NASDAQ:EXOZ) CEO Acquires 1,040 Shares of Stock

July 3, 2025 | insidertrades.com

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

June 26, 2025 | accessnewswire.comA

eXoZymes Increases CEO Compensation Package

June 20, 2025 | tipranks.com

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

May 16, 2025 | accessnewswire.comA

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

May 12, 2025 | accessnewswire.comA

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

May 7, 2025 | accessnewswire.comA

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

May 6, 2025 | accessnewswire.comA

Bringing clarity and precision to the cell-free space by introducing exozymes

April 21, 2025 | globenewswire.com

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

April 10, 2025 | globenewswire.com

eXoZymes Inc. Reports 2024 Progress and IPO Success

April 2, 2025 | tipranks.com

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

April 2, 2025 | globenewswire.com

eXoZymes Provides Fourth Quarter and Full Year 2024 Update

April 2, 2025 | globenewswire.com

eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ, AMRN, CAPR, and CTMX Company Descriptions

Amarin NASDAQ:AMRN

$15.46 -0.01 (-0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$15.46 0.00 (0.00%)

As of 04:04 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Capricor Therapeutics NASDAQ:CAPR

$6.27 +0.02 (+0.35%)

Closing price 03:59 PM Eastern

Extended Trading

$6.27 0.00 (-0.03%)

As of 04:04 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CytomX Therapeutics NASDAQ:CTMX

$2.06 -0.02 (-0.72%)

Closing price 03:59 PM Eastern

Extended Trading

$2.06 0.00 (0.00%)

As of 04:05 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

eXoZymes NASDAQ:EXOZ

$9.70 +0.39 (+4.19%)

As of 08/27/2025 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time